Engaging SBIR Resources for Development of Surgical Innovations in Oncology

Narayanan, Deepa; Canaria, Christie A.; Pond, Monique A; Weingarten, Michael

doi:10.1007/978-3-030-18613-5_14

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2021, the NCI SBIR Development Center provided ~$180 million in non‐dilutive funding to small businesses developing innovative technologies to prevent, diagnose, and treat cancer. The NCI SBIR Development Center has a centralized model for managing SBIR/STTR programs, and in addition to funding, the staff supports their portfolio companies with a variety of critical commercialization resources, 2 such as entrepreneurial training, access to investor networks, 3 and recently regulatory assistance in collaboration with the US Food and Drug Administration (FDA).…”

Section: Introductionmentioning

confidence: 99%

CARE program: NCI and FDA interagency collaborations to support oncology small business entrepreneurs

Pond

Narayanan

Zhang

et al. 2023

Clinical Translational Sci

Self Cite

View full text Add to dashboard Cite

The National Cancer Institute's Small Business Innovation Research Development Center (NCI SBIR) supports the commercialization of novel cancer-related technologies by providing resources to 300-400 small businesses each year. Whereas Federal funding is crucial for the translation of technologies to the clinic, the ma-How to cite this article: Pond MA, Narayanan D, Zhang K, et al. CARE program: NCI and FDA interagency collaborations to support oncology small business entrepreneurs.

show abstract

Section: Introductionmentioning

confidence: 99%

CARE program: NCI and FDA interagency collaborations to support oncology small business entrepreneurs

Pond

Narayanan

Zhang

et al. 2023

Clinical Translational Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…The program has a unique management structure 1 and has been managed centrally through the SBIR Development Center since 2008. This centralized management focuses on supporting companies that are product‐focused and committed to getting technologies into the clinic by providing not only nondilutive capital but also a variety of critical commercialization resources, 2 like entrepreneurship training and access to expertise. One such resource essential for the commercialization of NCI SBIR‐funded technologies is the Investor Initiatives program developed to effectively connect portfolio companies with third‐party investors and strategic partners (Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

Investor initiatives program: Public‐private partnerships to expedite commercialization for NCI‐funded small business entrepreneurs

Connors

Lou

Subedee

et al. 2021

Clinical Translational Sci

Self Cite

View full text Add to dashboard Cite

The National Cancer Institute's Small Business Innovation Research Development Center (NCI SBIR) provides federal research and development funding and commercialization resources to more than 400 small businesses each year developing novel technologies to prevent, diagnose, and treat cancer. Although federal funding is vital for life science startups at the early stage of development, it is often insufficient to translate the technology from discovery to commercial product. Early-stage startups must connect to follow-on capital and resources to bring NCI-funded technologies to patients. Most startups face challenges in securing additional funding due to lack of access to investors and strategic partners and the ability to effectively pitch their technology. In 2015, the NCI SBIR started the Investor Initiatives program to connect funded small businesses with targeted investors and strategic partners to address the aforementioned obstacles. This program leverages an extensive network of investors and partners to conduct business-focused reviews and provide pitch coaching. The program incentivizes earlier collaborations between NCI-funded companies and private investors through various channels. The program has supported 117 companies from years 2016-2019 to attend 27 investor showcase events. Follow-up surveys show that the program and the assistance offered by NCI SBIR have contributed to a total of 32 completed deals as of April 29, 2020. This paper will discuss the Investor Initiatives program and its outcomes from 2016 to 2019 and demonstrate the effectiveness of a federal program that leverages public-private partnerships to assist portfolio companies with raising follow-on funding to accelerate the translation of research into clinical practice.

show abstract

Engaging SBIR Resources for Development of Surgical Innovations in Oncology

Cited by 2 publications

References 3 publications

CARE program: NCI and FDA interagency collaborations to support oncology small business entrepreneurs

CARE program: NCI and FDA interagency collaborations to support oncology small business entrepreneurs

Investor initiatives program: Public‐private partnerships to expedite commercialization for NCI‐funded small business entrepreneurs

Contact Info

Product

Resources

About